Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders

Journal of Pharmacological and Toxicological Methods

Volumn 66, Issue 3, 2012, Pages 215-220

  Konsoula, Zacharoula ^a   Barile, Frank A ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

Author keywords

Acetylation; Deacetylases; Epigenetic; HDAC inhibitors; Histone modification; Neurodegenerative disease

Indexed keywords

4 PHENYLBUTYRIC ACID; ALPHA TUBULIN; AMYLOID BETA PROTEIN; BETA SECRETASE 1; BUTYRIC ACID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE 5; GAMMA SECRETASE; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HUNTINGTIN; PRESENILIN 1; PRESENILIN 2; SIRTUIN 1; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; AMNESIA; ARTICLE; CHROMATIN; DEACETYLATION; DEGENERATIVE DISEASE; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; GENE REPRESSION; HISTONE ACETYLATION; HUNTINGTON CHOREA; LEARNING; MEMORY; MEMORY DISORDER; NERVE CELL PLASTICITY; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SUBSTANTIA NIGRA PARS COMPACTA; TRANSCRIPTION INITIATION;

EID: 84870667053     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2012.08.001     Document Type: Article

References (52)

1. Abel, T., & Zukin, R. S. (2008). Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Current Opinion in Pharmacology, 8, 57-64.
2. Acharya, M. R., Sparreboom, A., Venitz, J., & Figg, W. D. (2005). Rational development of histone deacetylase inhibitors as anticancer agents: A review. Molecular Pharmacology, 68, 917-932.
3. Airaksinen, M. S., & Saarma, M. (2002). The GDNF family: Signaling, biological functions and therapeutic value. Nature Reviews Neuroscience, 3, 383-394.
4. Alenghat, T., Meyers, K., Mullican, S. E., Leitner, K., Adeniji-Adele, A., Avila, J., et al. (2008). Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature, 456, 997-1000.
5. Bardai, F. H., & D'Mello, S. R. (2011). Selective toxicity by HDAC3 in neurons: Regulation by Akt and GSK3β. Journal of Neuroscience, 31, 1746-1751.
6. Cao, X., & Südhof, T. C. (2001). A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science, 293, 115-120.
7. Chen, P. S., Peng, G. S., Li, G., Yang, S., Wu, X.,Wang, C. C., et al. (2006). Valproate protects dopaminergic neurons inmidbrain neuron/glia cultures by stimulating the release of neurotrophic factors fromastrocytes. Molecular Psychiatry, 11, 1116-1125.
8. Cruz, J. C., Tseng, H. C., Goldman, J. A., Shih, H., & Tsai, L. H. (2003). Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron, 40, 471-483.
9. Dauer, W., & Przedborski, S. (2003). Parkinson's disease: Review mechanisms and models. Neuron, 39, 889-909.
10. Ding, H., Dolan, P. J., & Johnson, G. V. (2008). Histone deacetylase 6 interacts with the microtubule-associated protein tau. Journal of Neurochemistry, 106, 2119-2130.
11. Donmez, G., Wang, D., Cohen, D. E., & Guarente, L. (2010). SIRT1suppresses β-amyloid production by activating the α-secretase gene ADAM10. Cell, 142, 320-332.
12. Ferrante, R. J., Kubilus, J. K., Lee, J., Ryu, H., Beesen, A., & Zucker, B. (2003). Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. Journal of Neuroscience, 23, 9418-9427.
13. Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., & Tsai, L. H. (2007). Recovery of learning and memory is associated with chromatin remodelling. Nature, 447, 178-182.
14. Fischle, W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, W., et al. (2002). Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Molecular Cell, 9, 45-57.
15. Francis, Y. I., Fa, M., Ashraf, H., Zhang, H., Staniszewski, A., Latchman, D. S., et al. (2009). Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. Journal of Alzheimer's Disease, 18, 131-139.
16. Gao, J.,Wang,W. Y.,Mao, Y.W., Gräff, J., Guan, J. S., Pan, L., et al. (2010). A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature, 466, 1105-1109.
17. Gardian, G., Browne, S. E., Choi, D. K., Klivenyi, P., Gregorio, J., Kubilus, J. K., et al. (2005). Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. Journal of Biological Chemistry, 280, 556-563.
18. Gardian, G., Yang, L., Cleren, C., Calingasan, N. Y., Klivenyi, P., & Beal, M. F. (2004). Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Medicine, 5, 235-241.
19. Green, K. N., Steffan, J. S., Martinez-Coria, H., Sun, X., Schreiber, S. S., Thompson, L. M., et al. (2008). Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. Journal of Neuroscience, 28, 11500-11510.
20. Guan, J. S., Haggarty, S. J., Giacometti, E., Dannenberg, J. H., Joseph, N., Gao, J., et al. (2009). HDAC2 negatively regulates memory formation and synaptic plasticity. Nature, 459, 55-60.
21. Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science, 297, 353-356.
22. Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., et al. (2003). Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America, 100, 2041-2046.
23. Hodges, A., Strand, A. D., Aragaki, A. K., Kuhn, A., Sengstag, T., & Hughes, G. (2006). Regional and cellular gene expression changes in human Huntington's disease brain. Human Molecular Genetics, 15, 965-977.
24. Holliday, R. (1990). Mechanisms for the control of gene activity during development. Biological Reviews of the Cambridge Philosophical Society, 65, 431-471.
25. Iwata, A., Riley, B. E., Johnston, J. A., & Kopito, R. R. (2005). HDAC6 and microtubules are required for autophagic degradation of aggregated Huntington. Journal of Biological Chemistry, 280, 40282-40292.
26. Jackson-Lewis, V., Blesa, J., & Przedborski, S. (2012). Animal models of Parkinson's disease. Parkinsonism & Related Disorders, 18, S183-S185.
27. Kilgore, M., Miller, C. A., Fass, D. M., Hennig, K. M., Haggarty, S. J., Sweatt, J. D., et al. (2010). Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology, 35, 870-880.
28. Kontopoulos, E., Parvin, J. D., & Feany, M. B. (2006). Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Human Molecular Genetics, 15, 3012-3023.
29. Landrigan, P. J., Sonawane, B., Butler, R. N., Trasande, L., Callan, R., & Droller, D. (2005). Early environmental origins of neurodegenerative disease in later life. Environmental Health Perspectives, 113, 1230-1233.
30. Mai, A., Massa, S., Rotili, D., Cerbara, I., Valente, S., Pezzi, R., et al. (2005). Histone deacetylation in epigenetics: An attractive target for anticancer therapy. Medical Research Reviews, 25, 261-309.
31. Marks, P. A., Miller, T., & Richon, V. M. (2003). Histone deacetylases. Current Opinions in Pharmacology, 3, 344-351.
32. Mattson, M. P. (2004). Pathways towards and away from Alzheimer's disease. Nature, 430, 631-639.
33. McCampbell, A., Taye, A. A., Whitty, L., Penney, E., Steffan, J. S., & Fischbeck, K. H. (2001). Histone deacetylase inhibitors reduce polyglutamine toxicity. Proceedings of the National Academy of Sciences of the United States of America, 98, 15179-15184.
34. McQuown, S. C., & Wood, M. A. (2011). HDAC3 and the molecular brake pad hypothesis. Neurobiology of Learning and Memory, 96, 27-34.
35. Outeiro, T. F., Kontopoulos, E., Altmann, S. M., Kufareva, I., Strathearn, K. E., Amore, A. M., et al. (2007). Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science, 317, 516-519.
36. Peleg, S., Sananbenesi, F., Zovoilis, A., Burkhardt, S., Bahari-Javan, S., Agis-Balboa, R. C., et al. (2010). Altered histone acetylation is associated with age-dependent memory impairment in mice. Science, 328, 753-756.
37. Perez, M., Santa-Maria, I., Gomez de Barreda, E., Zhu, X., Cuadros, R., Cabrero, J. R., et al. (2009). Tau-An inhibitor of deacetylase HDAC6 function. Journal of Neurochemistry, 109, 1756-1766.
38. Probst, A. V., Dunleavy, E., & Almouzni, G. (2009). Epigenetic inheritance during the cell cycle. Nature Reviews Cell Biology, 10, 192-206.
39. Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen, L., et al. (2006). Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. Journal of Biological Chemistry, 281, 21745-21754.
40. Qing, H., He, G., Ly, P. T., Fox, C. J., Staufenbiel, M., Cai, F., et al. (2008). Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. The Journal of Experimental Medicine, 205, 2781-2789.
41. Rasheed, W. K., Johnstone, R. W., & Prince, H. M. (2007). Histone deacetylase inhibitors in cancer therapy. Expert Opinion on Investigational Drugs, 16, 659-678.
42. Ricobaraza, A., Cuadrado-Tejedor, M., Marco, S., Pérez-Otaño, I., & García-Osta, A. (2012). Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus, 22, 1040-1050.
43. Ricobaraza, A., Cuadrado-Tejedor, M., Perez-Mediavilla, A., Frechilla, D., Del Rio, J., & Garcia-Osta, A. (2009). Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology, 34, 1721-1732.
44. Sadri-Vakili, G., Bouzou, B., Benn, C. L., Kim, M. O., Chawla, P., Overland, R. P., et al. (2007). Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Human Molecular Genetics, 16, 1293-1306.
45. Santibanez, M., Bolumar, F., & Garcia, A. M. (2007). Occupational risk factors in Alzheimer's disease: A review assessing the quality of published epidemiological studies. Occupational and Environmental Medicine, 64, 723-732.
46. Sanyal, J., Chakraborty, D. P., Sarkar, B., Banerjee, T. K., Mukherjee, S. C., Ray, B. C., et al. (2010). Environmental and familial risk factors of Parkinson's disease: Casecontrol study. Canadian Journal of Neurological Sciences, 37, 637-642.
47. Thomas, E. A., Coppola, G., Desplats, P. A., Tang, B., Soragni, E., Burnett, R., et al. (2008). The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 105, 15564-15569.
48. Volpe, T. A., Kidner, C., Hall, I. M., Teng, G., Grewal, S. I., & Martienssen, R. A. (2002). Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi. Science, 297, 1833-1837.
49. Wood, M. A., Hawk, J. D., & Abe, T. (2006). Combinatorial chromatin modifications and memory storage: A code for memory? Learning & Memory (Cold Spring Harbor, N.Y.), 13, 241-244.
50. Wu, X., Chen, P. S., Dallas, S., Wilson, B., Block, M. L., Wang, C. C., et al. (2008). Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. The International Journal of Neuropsychopharmacology, 11, 1123-1134.
51. Zhang, Y., LeRoy, G., Seelig, H. P., Lane, W. S., & Reinberg, D. (1998). The dermatomyositisspecific auto-antigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell, 95, 279-289.
52. Zhang, X., Yuan, Z., Zhang, Y., Yong, S., Salas-Burgos, A., & Koomen, J. (2007). HDAC6 modulates cell motility by altering the acetylation level of cortactin. Molecular Cell, 27, 197-213.